Sort
10,766 grants matching “checkpoint inhibitor”
Core B: Computational
$371,187Alan S Perelson · Beth Israel Deaconess Medical Center · P01 · FY2018 · AI
Antitumor-Antibiotics from Marine Microorganisms
$371,070William Fenical · University Of California, San Diego · R37 · FY2006 · CA
Development of a Novel Nectin Targeting Antibody-drug Conjugate for Ovarian Cancer Therapy
$371,070Oliver Delgado · Resonant Therapeutics, Inc. · R43 · FY2024 · CA
Early development of small molecule dendritic cell immunopotentiators for the treatment of solid tumors
$370,994Sumit K Chanda · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2021 · CA
Genetic regulation of genome stability in yeast
$370,868Thomas D Petes · Duke University · R01 · FY2006 · GM
Fostriecin and Related Protein Phosphatase Inhibitors
$370,863Scripps Research Institute · R01 · FY2005 · CA
Fostriecin and Related Protein Phosphatase Inhibitors
$370,863Scripps Research Institute · R01 · FY2004 · CA
Fostriecin and Related Protein Phosphatase Inhibitors
$370,863Scripps Research Institute · R01 · FY2003 · CA
Fostriecin and Related Protein Phosphatase Inhibitors
$370,863Scripps Research Institute · R01 · FY2002 · CA
Synthesis and evaluation of BTN3A1 ligands for cancer immunotherapy
$370,809Andrew J Wiemer · University Of Connecticut Storrs · R01 · FY2025 · CA
Abbreviated targeted therapy to improve anti-PD-1 inhibitor efficacy in melanoma
$370,800Ryan J Sullivan · Massachusetts General Hospital · R01 · FY2019 · CA
Development and Mechanistic Studies of an Engineered Human Enzyme to Abrogate Immune Suppression due to Elevated Methylthioadenosine (MTA) by MTAP null/low Tumors
$370,782Everett Stone · University Of Texas At Austin · R01 · FY2022 · CA
Development and Mechanistic Studies of an Engineered Human Enzyme to Abrogate Immune Suppression due to Elevated Methylthioadenosine (MTA) by MTAP null/low Tumors
$370,782Everett Stone · University Of Texas At Austin · R01 · FY2023 · CA
Ethnicity-determined T cell responses and GARP/TGFbeta1 signaling in prostate cancer
$370,628Xiaolin Zi · University Of California-Irvine · R01 · FY2022 · CA
Role of Nuclear Pore-Regulated Mechanisms in Prostate Cancer Aggressiveness
$370,612Veronica Rodriguez-Bravo · Mayo Clinic Rochester · R01 · FY2024 · CA
Dissecting and targeting mechanisms of genomic instability-triggered immune evasion in RBM10-deficient non-small cell lung cancer
$370,575Ferdinandos Skoulidis · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitors
$370,575Timothy Anthony Yap · University Of Tx Md Anderson Can Ctr · R01 · FY2021 · CA
Mechanism-rooted therapeutic strategies for immune-related toxicities induced by checkpoint inhibitors
$370,575Roza Insafetdinovna Nurieva · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Paradoxical roles of tumor lymphangiogenesis on tumor immunity and implications for immunotherapy - Resubmission 01
$370,575Melody A Swartz · University Of Chicago · R01 · FY2021 · CA
Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitors
$370,575Timothy Anthony Yap · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Paradoxical roles of tumor lymphangiogenesis on tumor immunity and implications for immunotherapy - Resubmission 01
$370,575Melody A Swartz · University Of Chicago · R01 · FY2020 · CA
Understanding and harnessing immune-modulatory effects of covalent KRASG12C inhibitors in KRASG12C-mutant non-small cell lung cancer
$370,575Ferdinandos Skoulidis · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Dissecting and targeting mechanisms of genomic instability-triggered immune evasion in RBM10-deficient non-small cell lung cancer
$370,575Ferdinandos Skoulidis · University Of Tx Md Anderson Can Ctr · R01 · FY2025 · CA
Mechanism-rooted therapeutic strategies for immune-related toxicities induced by checkpoint inhibitors
$370,575Roza Insafetdinovna Nurieva · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
Transcriptomic mechanisms underlying the immune modulating function and therapeutic efficacy of PARP inhibitors
$370,575Timothy Anthony Yap · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA